Deep Dive Into Biogen Stock: Analyst Perspectives (17 Ratings)
Portfolio Pulse from Benzinga Insights
Analysts' ratings for Biogen (NASDAQ:BIIB) over the last quarter show a mix of bullish and bearish sentiments. The average 12-month price target has increased slightly to $274.41. Recent analyst actions include maintaining, raising, and lowering ratings and price targets, reflecting varied perceptions of Biogen's market standing.
May 22, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Analysts' ratings for Biogen show mixed sentiments with a slight increase in the average 12-month price target to $274.41. Recent actions include maintaining, raising, and lowering ratings, reflecting varied perceptions of Biogen's market standing.
The mixed analyst ratings and slight increase in the average price target suggest a neutral short-term impact on Biogen's stock price. The varied actions by analysts indicate differing opinions on the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100